Glipizide Patent Expiration
Glipizide is used for managing hyperglycemia in diabetes through oral administration of a once-a-day sustained release dosage form of Glipizide. It was first introduced by Pfizer Inc
Glipizide Patents
Given below is the list of patents protecting Glipizide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Glucotrol Xl | USRE44459 | Method for lowering blood glucose |
Mar 26, 2019
(Expired) | Pfizer |
| Glucotrol Xl | US5591454 | Method for lowering blood glucose |
Jan 07, 2014
(Expired) | Pfizer |
Glipizide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Glipizide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer | Memorial Sloan Kettering Cancer Center | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers | University of Michigan | NA |
COMPLETED
(Jul 1, 2026)
| PHASE1 |
| Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans | Massachusetts General Hospital | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |